Skip to content

Author

Sammudeen Ibrahim

5 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Nov 2026

Abstract 8496: Left Ventricular Aneurysm and Thromboembolic Risk in Hypertropic Cardiomyopathy Without Atrial Fibrillation

Background: Left ventricular (LV) apical aneurysms occur in a subset of patients with hypertrophic cardiomyopathy (HCM) and have been associated with ventricular arrhythmias and sudden cardiac death. However, the independent thromboembolic risk attributable to LV aneurysm in HCM, particularly in the absence of atria...

Sammudeen Ibrahim, Zakia Mohammed, H. Noureldine et al. · 0 citations
Nov 2026

Abstract 5502: Oral Anticoagulation Monotherapy versus Combination Antithrombotic Therapy with Antiplatelet Following TAVR in Patients on Chronic Oral Anticoagulation

Introduction: Optimal antithrombotic management following transcatheter aortic valve replacement (TAVR) in patients with pre-existing indications for chronic oral anticoagulation (OAC) remains poorly defined. Current evidence, including the POPular TAVI trial, suggests OAC monotherapy may be sufficient, yet combinat...

H. N. Pham, M. Abdelnabi, Ramzi Ibrahim et al. · 0 citations
Nov 2026

Abstract 7770: Comparative Effectiveness of Direct Oral Anticoagulants in Preventing Post-Thrombotic Syndrome After Acute Deep Vein Thrombosis

Background: Post-thrombotic syndrome (PTS) is a common chronic complication following acute deep vein thrombosis (DVT), affecting up to 20-50% of patients and leading to impaired quality of life and increased healthcare utilization. While direct oral anticoagulants (DOACs) are widely used for venous thromboembolism...

A. Abdelkhalek, I. Ogieuhi, E. Okorigba et al. · 0 citations
Review Open access Aug 2026

Three-month versus twelve-month dual antiplatelet therapy after acute coronary syndrome: An updated meta-analysis of randomized trials with trial sequential analysis.

3-month DAPT followed by monotherapy significantly reduces bleeding without increasing ischemic events and crosses the futility boundary for MACCE and the benefit boundary for CRB, indicating conclusive evidence for bleeding reduction and futility for ischemic benefit.

C. Chinnatambi, Abdul Rahaman Ottun, Louise Sakowski et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.